AI-generated from publicly available materials.Remepy has successfully secured $36 million in funding to propel its Parkinson's treatment into Phase III clinical trials, marking a significant step in its innovative approach of integrating pharmaceuticals with therapeutic software.
This Series A funding round, co-led by Merck KGaA’s M Ventures and O.G. Venture Partners, elevates the startup's total funding to $62 million. The investment roster includes both existing and new stakeholders such as NFX, Vine Ventures, and PsyMed Ventures, among others. Co-CEOs Michal Tsur and Or Shoval emphasize that the future of medicine lies in combining breakthrough drugs with personalized intelligence to enhance patient outcomes.
Remepy is at the forefront of developing a unique treatment model that merges prescription medications with AI-driven therapeutic applications. This innovative platform utilizes real-time data to customize interventions across various domains, including physical and cognitive therapy. Earlier collaborations with Merck KGaA have already yielded promising results, particularly in exploring hybrid therapies for rare tumors and potential applications in managing pre-term birth.
The company’s lead program for Parkinson’s combines levodopa with a comprehensive digital protocol addressing diverse aspects of patient care. Promising Phase IIa results have shown notable improvements in both motor and non-motor symptoms. As Remepy gears up for its global Phase III trials later this year, interest from the medical community is growing, with a recent survey indicating that many physicians are more likely to prescribe drugs that integrate digital therapeutics, highlighting a shift towards more holistic treatment approaches in healthcare.